LABOMAR: NEW BIOCHETASI ACIDITA’ E DIGESTIONE STUDY IN VITRO

12 May 2022

Labomar SpA has carried, at the request of Alfasigma, a new study into the effects of Biochetasi Acidità e Digestione, a dietary supplement that helps regulate digestive processes and counteract stomach acidity.

The study, Antacid and Prodigestive Activity of a Novel Formulation, was published in the Journal of Gastrointestinal & Digestive System. This study, that also celebrates the milestone of the millionth package produced, demonstrated, for the first time in vitro, the antacid effect of Biochetasi Acidità e Digestione, acts against acidity and supports the digestion of proteins, fats and lactose with pro-digestive action. Labomar develops and produces the product for Alfasigma in two formats, powder sachets and chewable tablets.

Walter Bertin, founder and Chairperson of Labomar, noted: “This is an extraordinary result that confirms the properties of a product whose effectiveness had already been widely demonstrated […] This study also strengthens our partnership with Alfasigma, with whom we have a long-standing and mutually beneficial relationship”.

The complete press release is available in the RESULTS AND PRESS RELEASES section of our site.